Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:37 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery
NCT00778817 · National Cancer Institute (NCI) · PHASE2 · terminated · last registry update 2014-04-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The trial was permanently halted due to futility concerns.” | – | Registry record, National Cancer Institute (NCI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IGF1R within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2015-03-13Results posted on the registry: National Cancer Institute (NCI), linsitinib (NCT01533246)
- 2015-03-11Also stopped (withdrawn): Pfizer, figitumumab (NCT00635245)
- 2015-02-02Results posted on the registry: M.D. Anderson Cancer Center, Fulvestrant + MK-0646 (NCT00903006)
- 2015-02-02Also stopped (terminated): M.D. Anderson Cancer Center, Fulvestrant + MK-0646 (NCT00903006)
- 2015-01-14Results posted on the registry: SCRI Development Innovations, LLC, OSI-906 + Everolimus (NCT01154335)
- 2014-12-03Phase 3 first posted: National Cancer Institute (NCI), Cyclophosphamide + Doxorubicin (NCT02306161)
- 2014-11-19Also stopped (withdrawn): OHSU Knight Cancer Institute, erlotinib hydrochloride + linsitinib (NCT01465815)
- 2014-06-17Also stopped (withdrawn): Pfizer, CP-751,871 + Cisplatin (NCT00907504)
- 2014-06-09Results posted on the registry: Pfizer, CP-751,871 + Sunitinib (NCT00729833)
- 2014-06-09Also stopped (terminated): Pfizer, CP-751,871 + Sunitinib (NCT00729833)
- 2014-04-09Results posted on the registry: University of California, San Francisco, Nordihydroguaiaretic Acid (NDGA) (NCT00678015)
- 2014-04-09Also stopped (terminated): University of California, San Francisco, Nordihydroguaiaretic Acid (NDGA) (NCT00678015)
- 2014-02-28Results posted on the registry: Pfizer, CP-751,871 (NCT00560235)
- 2014-01-13Also stopped (terminated): Pfizer, CP-751,871 (Figitumumab) + Carboplatin (NCT00596830)
- 2013-12-17Results posted on the registry: Pfizer, CP-751,871 (NCT00474760)
- 2013-12-13Results posted on the registry: Pfizer, figitumumab + pegvisomant (NCT00976508)
- 2013-12-13Also stopped (terminated): Pfizer, figitumumab + pegvisomant (NCT00976508)
- 2013-12-03Results posted on the registry: Pfizer, CP-751,871 (Figitumumab) + Carboplatin (NCT00596830)
- 2013-11-20Also stopped (withdrawn): Emory University, OSI-906 and Pemetrexed (NCT01567384)
- 2013-10-21Also stopped (terminated): University of Colorado, Denver, OSI-906 + irinotecan (NCT01016860)
- 2013-08-27Results posted on the registry: Pfizer, CP-751,871 + Docetaxel (NCT01653158)
- 2013-07-24Results posted on the registry: Pfizer, CP 751,871 (Figitumumab) + Erlotinib (NCT00673049)
- 2013-07-24Also stopped (terminated): Pfizer, CP 751,871 (Figitumumab) + Erlotinib (NCT00673049)
- 2013-06-26Also stopped (withdrawn): Dana-Farber Cancer Institute, Gemcitabine, Erlotinib, OSI-906 + Gemcitabine, Erlotinib (NCT01600807)
- 2013-06-18Also stopped (terminated): Bristol-Myers Squibb, BMS-754807 + cetuximab (Erbitux®) (NCT00908024)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision